
LCTX Stock Forecast & Price Target
LCTX Analyst Ratings
Bulls say
Lineage Cell Therapeutics Inc. is demonstrating promising advancements in its clinical programs and manufacturing capabilities, particularly highlighted by the successful long-term Phase 1/2a data for OpRegen, which supports its efficacy in treating geographic atrophy. The company has reported a significant increase in revenue, rising to $6.6 million in the fourth quarter of 2025 from $2.9 million in the prior year, driven by collaboration revenue from its partnership with Roche and new research collaborations. Additionally, the achievement of key developmental milestones under its collaboration with Roche, including a $5 million payment, affirms the technical progress and reduces execution risk, enhancing Lineage's potential for future growth.
Bears say
Lineage Cell Therapeutics Inc. operates within a highly competitive and uncertain clinical biotechnology landscape, facing challenges related to the successful progression of its drug candidates, including OpRegen and OPC1, which could significantly impact future revenue streams. The company’s reliance on its proprietary AlloSCOPE cell-based manufacturing platform raises concerns regarding scalability and cost-effectiveness, particularly as it seeks to commercialize its therapies amid stringent regulatory requirements. Additionally, the financial strains due to ongoing research and development expenditures, combined with potential delays in clinical trials, may detrimentally affect the company's liquidity and overall financial stability, contributing to a negative outlook for its stock.
This aggregate rating is based on analysts' research of Lineage Cell Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LCTX Analyst Forecast & Price Prediction
Start investing in LCTX
Order type
Buy in
Order amount
Est. shares
0 shares